Therefore, we aimed to compare the PSMA expression on both prostate biopsy cores and pathological specimens with PSMA-PET findings in staging high-risk PCa patients eligible for radical prostatectomy (RP). This evidence concerns the gene FOLH1 and posterior cortical atrophy.